ALLMedicine™ Cirrhosis Center

Jun 28th, 2022 - Congenital bile acid synthesis defect (BASD) is a rare disease caused by mutations in the aldo-keto reductase 1D1 gene, which encodes the primary Δ4-3-oxosteroid 5β-reductase enzyme. Early disease diagnosis is critical for early treatment with bil...

Jun 28th, 2022 - Advanced chronic liver disease is considered a reversible condition after removal of the primary aetiological factor. This has led to a paradigm shift in which portal hypertension (PH) is a reversible complication of cirrhosis. The pharmacologic m...

Jun 27th, 2022 - LONDON – The novel liver-targeting agent fazirsiran has fared well in a small, but significant, study looking at its ability to improve liver histology in adults with alpha-1 antitrypsin (AAT) deficiency. Not only were serum and liver levels of th.

Jun 27th, 2022 - Chronic liver diseases are associated with the development of liver fibrosis. Without treatment, liver fibrosis commonly leads to cirrhosis and hepatocellular carcinoma. Fibroblast growth factor 12 (FGF12) is an intracrine factor belonging to the ...

Jun 27th, 2022 - Advances in hepatitis B virus (HBV) and hepatitis C virus (HCV) therapies have improved morbidity and mortality, but global disparities in viral hepatitis outcomes remain. We evaluate global trends in the impact of HBV and HCV on disability adjust...

Jun 7th, 2022 - Haemochromatosis is characterised by elevated transferrin saturation (TSAT) and progressive iron loading that mainly affects the liver. Early diagnosis and treatment by phlebotomy can prevent cirrhosis, hepatocellular carcinoma, diabetes, arthropa...

May 16th, 2022 - To provide evidence-based recommendations regarding the diagnosis and management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) to endocrinologists, primary care clinicians, health care professionals, and other...

Mar 19th, 2022 - The prevention and management of bleeding and thrombosis in patients with cirrhosis poses several difficult clinical questions. These Clinical Practice Guidelines have been developed to provide practical guidance on debated topics, including curre...

Sep 29th, 2021 - AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis.|2021|O'Shea RS,Davitkov P,Ko CW,Rajasekhar A,Su GL,|adverse effects,therapeutic use,drug effects,blood,diagnosis,drug therapy,standards,chemical...

Sep 29th, 2021 - AGA Technical Review on Coagulation in Cirrhosis.|2021|Intagliata NM,Davitkov P,Allen AM,Falck-Ytter YT,Stine JG,|adverse effects,therapeutic use,drug effects,blood,diagnosis,drug therapy,standards,chemically induced,blood,diagnosis,drug therapy,

Jun 24th, 2022 - Chronic hepatitis B affects at least 1.5 million Americans and is a major cause of cirrhosis, end-stage liver disease and hepatocellular carcinoma. Five oral antiviral agents have been licensed for use in chronic hepatitis B in the United States. ...

Jun 24th, 2022 - This is a general clinical research protocol to allow for evaluation, investigation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to study the natural history and pathogenesis of various l...

Jun 24th, 2022 - Telomere disease is caused by accelerated telomere attrition and results in multi-organ dysfunction. Telomeres are nucleotide repeats of non-coding DNA at the end of the chromosomes which function as protective caps to prevent erosion of genomic D...

Jun 24th, 2022 - Noncirrhotic Portal Hypertension (NCPH) includes a spectrum of chronic liver diseases characterized by increased pressure within the portal circulation in the absence of cirrhosis. The complications from NCPH are similar to that of cirrhosis induc...

Jun 24th, 2022 - Hepatitis C (HCV) is a leading cause of cirrhosis worldwide. Most complications associated with cirrhosis are driven by an altered portal circulation and the development of portal hypertension. Bacterial translocation (BT) from the gut to the syst...

Jun 27th, 2022 - LONDON – The novel liver-targeting agent fazirsiran has fared well in a small, but significant, study looking at its ability to improve liver histology in adults with alpha-1 antitrypsin (AAT) deficiency. Not only were serum and liver levels of th.

Jun 27th, 2022 - Pain is common in patients with cirrhosis, and its management presents significant challenges to health care providers, such as worries about GI bleeding, renal injury, falls, and hepatic encephalopathy. To address those issues, researchers at the...

Jun 27th, 2022 - LONDON ― Around the world, nonalcoholic fatty liver disease (NAFLD) has driven an increase in deaths from liver cancer over the past decade, overtaking alcoholic liver disease, hepatitis B, and hepatitis C, according to an analysis of the Global B...

Jun 24th, 2022 - Pain is common in patients with cirrhosis, and its management presents significant challenges to health care providers, such as worries about GI bleeding, renal injury, falls, and hepatic encephalopathy. To address those issues, researchers at the.

Jun 23rd, 2022 - Key clinical point: Nivolumab may serve as a first-line systemic treatment option in patients with hepatocellular carcinoma (HCC) and Child-Pugh B (CP-B) cirrhosis. Major finding: Patients receiving nivolumab vs.